Prescribing Patterns of Hydroxychloroquine and Corticosteroids Among Lupus Patients After New-onset End-stage Renal Disease.

Arthritis Care & Research
Anna BroderKaren H Costenbader

Abstract

Optimal strategies for managing lupus medications after end-stage renal disease (ESRD) have not been addressed. This study identifies the current United States-wide prescribing patterns of hydroxychloroquine (HCQ) and oral corticosteroids (CS), among SLE patients with incident ESRD enrolled in the US Renal Disease Systems (USRDS) registry. We identified incident ESRD patients ≥18 years with SLE as a primary cause of ESRD between January 2006 and June 2013. Patients who were started on dialysis at ESRD onset and enrolled in Medicare Part D within 93 days as required by Medicare were included. Among the 2654 new-onset ESRD patients with Part D, the median (IQR) duration of follow-up was 761 (374, 1375) days. At baseline, 1076 (41%) were not on HCQ or CS, 220 (8%) were prescribed HCQ alone, 509 (19%) were prescribed both HCQ and CS, and 849 (32%) were prescribed CS alone. Of the 1983 patients who either never received or discontinued HCQ after ESRD onset, 667 (34%) continued CS to the end of the follow-up period. The median (IQR) CS dose was lower for patients on HCQ (14 [9, 21] mg), compared to patients who were never prescribed HCQ (15 [9, 27] mg), or patients who discontinued HCQ after ESRD (17 [10, 27] mg), p=0.001. About one ...Continue Reading

Related Concepts

Related Feeds

Antimalarial Agents

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Antimalarial Agents (ASM)

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.